ReSViNet 2023 data reinforce AstraZeneca's commitment to help prevent Respiratory …

PUBLISHED 21 February 2023 21 February 2023 07:00 GMT   Beyfortus continues to demonstrate consistent protection against RSV disease through the RSV season New Canadian analysis demonstrates Synagis to be highly cost-effective in 29-35 weeks gestational age infants   AstraZeneca will showcase new data across its Vaccines and Immune Therapies Respiratory Syncytial Virus (RSV) portfolio at the 7th Respiratory Syncytial Virus Foundation (ReSViNET) Conference in Lisbon, Portugal from 22-24 February 2023, reinforcing its commitment to help protect infants from RSV. The Company is set to present five abstracts and posters at the event, including new data featuring Beyfortus (nirsevimab) and Synagis (palivizumab). Iskra Reic, Executive Vice President, Vaccines and Immune Therapies, AstraZeneca, said: “I am proud of AstraZeneca’s commitment to respiratory syncytial virus (RSV) and our continued focus on innovating antibodies to provide protection to the most vulnerable. We believe that Beyfortus has the potential to transform the medical community’s approach to preventing RSV infections in infants, and this is of particular importance given the recent surges of the virus amongst infants this past winter season.” Underscoring the continued need for RSV protection AstraZeneca is working with the global clinical community to advance the understanding of RSV and is partnering
Read More